Welcome to the our Aesthetic Medicine news roundup, 15 July 2022.
AbbVie’s aesthetics products bounce back, smoothing investors’ pandemic-induced worry lines
AbbVie’s $63 billion acquisition of Allergan was motivated in large part by the Illinois-based company’s belief in the blockbuster wrinkle treatment Botox—and its growth prospects.
IPL With Skincare Enhances Rosacea Outcomes
A skincare regimen that includes a phyto-corrective mask, gel, and resveratrol antioxidant serum may complement intense pulsed light (IPL)-based treatments for patients with rosacea and enhance outcomes, researchers reported in the Journal of Cosmetic Dermatology.
AbbVie puts an end to Botox trade secrets suit, imposes royalty, license deal on competitor Evolus
The crown jewel of AbbVie’s big-dollar acquisition of Allergan, Botox is one of the most recognizable brands in pharma — and both drugmakers have worked overtime to protect its advantage. After scoring a fatal blow to Evolus’ chances as a major competitor late last year, AbbVie is now putting the icing on the cake.
South Korean company nabs plant that makes generic Botox
PharmaResearch Products, a South Korean company focused on “regenerative” and cosmetic medicines has picked up a plant that manufactures generic injectable botulinum toxin, the same ingredient used in the popular wrinkle remover Botox.
‘Dangerous to the public’: Celebrity cosmetic surgeon suspended amid probe
A former associate of celebrity cosmetic surgeon Daniel Lanzer has been suspended by the national health regulator just two weeks after posting on social media he had the backing of the state regulator “who had no concerns with my facilities or practices”.
Russia’s plastic surgery sector feels pinch from western sanctions
When it comes to looking good, Russian women are happy to splash out, even on a bit of nip-and-tuck plastic surgery.
Opportunities in China’s beauty value economy
What are the drivers for the phenomenal growth in China’s hair care, anti-aging, and aesthetic medicine and cosmetic surgery markets?
